Psoralidin / CD31 Cancer Research Results

PSO, Psoralidin: Click to Expand ⟱
Features:
Psoralidin is a prenylated coumestan isolated primarily from Psoralea corylifolia (Babchi). It is not a classical anticancer drug.
Psoralidin generally acts to suppress oncogenic signaling and survival pathways while promoting apoptosis in tumor cells.
Reported effects (context-dependent, preclinical):
-DOWNREGULATES pro-survival pathways (e.g., NF-κB, STAT3)
-UPREGULATES apoptotic signaling (caspase activation)
-MODULATES androgen receptor signaling in prostate cancer models
-SENSITIZES tumor cells to chemo- and radio-induced stress

This positions psoralidin as a biologic modulator, not a driver.

Across cancer cell and animal models, psoralidin has been associated with:
-Apoptosis induction
  -Caspase activation
  -Mitochondrial depolarization
-Inflammatory pathway suppression
  -NF-κB inhibition
  -STAT3 attenuation
-Hormone signaling modulation
  -Androgen receptor suppression (prostate cancer context)
-Oxidative stress interaction
  -Redox imbalance tipping tumor cells toward death under stress

Psoralidin is best described as chemopreventive or chemo-sensitizing, not chemoprotective


CD31, platelet endothelial cell adhesion molecule-1 (PECAM-1): Click to Expand ⟱
Source:
Type: marker
CD31, also known as platelet endothelial cell adhesion molecule-1 (PECAM-1), is a transmembrane receptor that plays a crucial role in various cellular processes, including cell adhesion, migration, and signaling.
High CD31 expression has been linked to poor prognosis and increased metastasis. (except Leukemia and brain cancers).
CD31 is a marker that is commonly used to identify microvessels in tissue sections.


Scientific Papers found: Click to Expand⟱
4968- PSO,    Psoralidin: emerging biological activities of therapeutic benefits and its potential utility in cervical cancer
- in-vitro, Cerv, NA
*Inflam↓, *antiOx↑, *neuroP↑, *AntiDiabetic↑, *Bacteria↓, AntiTum↑, CSCs↓, ROS↑, TumAuto↑, Apoptosis↑, ChemoSen↑, RadioS↑, BioAv↓, *cardioP↑, *ROS↓, *LDH↓, TumCP↓, TRAIL⇅, TumCMig↓, EMT↓, NF-kB↓, P53↑, Casp3↑, NOTCH↓, CSCs↓, angioG↓, VEGF↓, Ki-67↓, CD31↓, TRAILR↑, MMP↓, BioAv↓, BioAv↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

ROS↑, 1,  

Mitochondria & Bioenergetics

MMP↓, 1,  

Cell Death

Apoptosis↑, 1,   Casp3↑, 1,   TRAIL⇅, 1,   TRAILR↑, 1,  

Autophagy & Lysosomes

TumAuto↑, 1,  

DNA Damage & Repair

P53↑, 1,  

Proliferation, Differentiation & Cell State

CSCs↓, 2,   EMT↓, 1,   NOTCH↓, 1,  

Migration

CD31↓, 1,   Ki-67↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling

NF-kB↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 2,   BioAv↑, 1,   ChemoSen↑, 1,   RadioS↑, 1,  

Clinical Biomarkers

Ki-67↓, 1,  

Functional Outcomes

AntiTum↑, 1,  
Total Targets: 24

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis

LDH↓, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,  

Clinical Biomarkers

LDH↓, 1,  

Functional Outcomes

AntiDiabetic↑, 1,   cardioP↑, 1,   neuroP↑, 1,  

Infection & Microbiome

Bacteria↓, 1,  
Total Targets: 9

Scientific Paper Hit Count for: CD31, platelet endothelial cell adhesion molecule-1 (PECAM-1)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:389  Target#:295  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page